Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death

Multiple myeloma (MM) is a common hematological disease characterized by the accumulation of clonal malignant plasma cells in the bone marrow. Over the past two decades, new therapeutic strategies have significantly improved the treatment outcome and patients survival. Nevertheless, most MM patients...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-05, Vol.13 (10), p.2411
Main Authors: Caillot, Mélody, Dakik, Hassan, Mazurier, Frédéric, Sola, Brigitte
Format: Article
Language:English
Subjects:
Antioxidants
Apoptosis
Bone marrow
Cancer
Cell death
Cellular Biology
Drug resistance
Endoplasmic reticulum
Enzymes
Free radicals
Granulocytes
Growth factors
Hematological diseases
Hematology
Homeostasis
Human health and pathology
Hypoxia
Immunoglobulins
Kinases
Life Sciences
Lipids
Metabolism
Multiple myeloma
Oxidation
Oxidative stress
Patients
Pharmaceutical sciences
Pharmacology
Phosphorylation
Plasma cells
Proteasome inhibitors
Proteins
Reactive oxygen species
Review
Transcription factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple myeloma (MM) is a common hematological disease characterized by the accumulation of clonal malignant plasma cells in the bone marrow. Over the past two decades, new therapeutic strategies have significantly improved the treatment outcome and patients survival. Nevertheless, most MM patients relapse underlying the need of new therapeutic approaches. Plasma cells are prone to produce large amounts of immunoglobulins causing the production of intracellular ROS. Although adapted to high level of ROS, MM cells die when exposed to drugs increasing ROS production either directly or by inhibiting antioxidant enzymes. In this review, we discuss the efficacy of ROS-generating drugs for inducing MM cell death and counteracting acquired drug resistance specifically toward proteasome inhibitors.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13102411